title: Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats.
abstract: Sirtuin 1 (SIRT1) and its activator resveratrol are emerging as major regulators of metabolic processes. We investigate the site of resveratrol action on glucose metabolism and the contribution of SIRT1 to these effects. Because the arcuate nucleus in the mediobasal hypothalamus (MBH) plays a pivotal role in integrating peripheral metabolic responses to nutrients and hormones, we examined whether the actions of resveratrol are mediated at the MBH.
  
  
  
  Sprague Dawley (SD) male rats received acute central (MBH) or systemic injections of vehicle, resveratrol, or SIRT1 inhibitor during basal pancreatic insulin clamp studies. To delineate the pathway(s) by which MBH resveratrol modulates hepatic glucose production, we silenced hypothalamic SIRT1 expression using a short hairpin RNA (shRNA) inhibited the hypothalamic ATP-sensitive potassium (K(ATP)) channel with glibenclamide, or selectively transected the hepatic branch of the vagus nerve while infusing resveratrol centrally.
  
  
  
  Our studies show that marked improvement in insulin sensitivity can be elicited by acute administration of resveratrol to the MBH or during acute systemic administration. Selective inhibition of hypothalamic SIRT1 using a cell-permeable SIRT1 inhibitor or SIRT1-shRNA negated the effect of central and peripheral resveratrol on glucose production. Blockade of the K(ATP) channel and hepatic vagotomy significantly attenuated the effect of central resveratrol on hepatic glucose production. In addition, we found no evidence for hypothalamic AMPK activation after MBH resveratrol administration.
  
  
  
  Taken together, these studies demonstrate that resveratrol improves glucose homeostasis mainly through a central SIRT1-dependent pathway and that the MBH is a major site of resveratrol action.
authors: Department of Medicine, Diabetes Research Center, Albert EinsteinCollege of Medicine, Bronx, New York, USA. colette.knight@einstein.yu.edu
authors: Colette M
authors: CM
authors: Knight
authors: Roger
authors: R
authors: Gutierrez-Juarez
authors: Tony K T
authors: TK
authors: Lam
authors: Isabel
authors: I
authors: Arrieta-Cruz
authors: Loli
authors: L
authors: Huang
authors: Gary
authors: G
authors: Schwartz
authors: Nir
authors: N
authors: Barzilai
authors: Luciano
authors: L
authors: Rossetti
mesh_terms: D000818:Animals; D020536:Enzyme Activators / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D020868:Gene Silencing; D005947:Glucose / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007033:Hypothalamus, Middle / Q000187:drug effects* / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology*; D007329:Insulin Antagonists / Q000494:pharmacology; D007333:Insulin Resistance; D054086:KATP Channels / Q000037:antagonists & inhibitors; D008099:Liver / Q000187:drug effects* / Q000294:innervation / Q000378:metabolism; D008297:Male; D009928:Organ Specificity; D026902:Potassium Channel Blockers / Q000494:pharmacology; D034741:RNA, Small Interfering; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D056564:Sirtuin 1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013267:Stilbenes / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*
chemical_list: D020536:Enzyme Activators; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D007329:Insulin Antagonists; D054086:KATP Channels; D026902:Potassium Channel Blockers; D034741:RNA, Small Interfering; D013267:Stilbenes; C488368:Sirt1 protein, rat; D056564:Sirtuin 1; D005947:Glucose; D000077185:Resveratrol